PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Customers are to be offered discounted weight loss treatments through insurance giant Vitality in a UK first. The group, ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

An academic study of the merger hopes to give insight into how attorneys general can strengthen certificate-of-need laws and the importance of having more power over sales. Other industry news focuses ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress. The company's breakthroughs are paying off. In each of the past six ...